Company intelligence / Profile preview
Elios Therapeutics
Austin, Texas, United Stateseliostherapeutics.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Elios Therapeutics develops personalized therapeutic cancer vaccines using a proprietary delivery system to stimulate both innate and adaptive immunity. Their lead candidate, TLPLDC, has reached Phase 2 clinical development targeting metastatic melanoma and other solid tumors. The company focuses on addressing unmet needs in oncology through autologous immunotherapies designed to generate durable anti-tumor responses.
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic cancer vaccines (autologous)immunotherapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Elios Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elios Therapeutics.